Seeking Alpha
 

Oncothyreon Inc . (ONTY)

- NASDAQ
  • Aug. 7, 2012, 5:35 PM
    Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX
    | 2 Comments
  • May. 7, 2012, 5:03 PM
    Oncothyreon (ONTY): Q1 EPS of $0.21 may not be comparable to consensus of by -$0.17. Shares -0.9% AH. (PR)
    | 1 Comment
  • Mar. 29, 2012, 9:15 AM
    Premarket gainers: PSS +11%. RHT +7%. THLS +6%. ILMN +4%. ZLCS +3%. HERO +3%. BNNY +3%.
    Losers: CHTP -29%. NBG -6%. NCT -5%. JBLU -4%. BBY -4%. ATPG -3%. ONTY -3%. MTL -3%. ING -3%. BCS -3%. VVUS -3%. ARNA -3%. TOT -3%.
    | Comment!
  • Mar. 28, 2012, 4:40 PM
    Oncothyreon (ONTY) -5.1% AH after announcing a stock offering of undisclosed size. The company plans to use the proceeds to fund the development of its PX-866 cancer drug, as well as its ONT-10 vaccine. (PR)
    | Comment!
  • Mar. 6, 2012, 9:05 AM
    Premarket gainers: VRML +14%. HNR +12%. CYTK +10%. NBG +8%. MWW +7%.
    Losers: ONTY -40%. ZLTQ -14%. AEZS -12%. NTRI -11%. KERX -8%. RAS -6%. VVUS -6%. CNX -5%.
    | Comment!
  • Mar. 6, 2012, 6:52 AM
    Shares of Oncothyreon (ONTY) fall 32.4% in premarket trading after Merck KgaA (MKGAF.PK) announces that studies on the experimental lung-cancer drug Stimuvax won't be completed until next year. Stimuvax is being developed by Merck KGaA under a license agreement with Oncothyreon.
    | Comment!
  • Jan. 24, 2012, 8:57 AM
    Shares of Oncothyreon (ONTY) get a lift from a price target increase from JMP Securities. Analyst with the firm raise their PT to $14 from $8 - marking 125% upside potential. Shares +3.7% premarket.
    | 1 Comment
  • Dec. 23, 2011, 9:56 AM
    Oncothyreon (ONTY -2.1%) trades lower after the firm files (S-3) a shelf registration with the SEC to sell up to $150M in securities including common stock, preferred shares, debt issues, and warrants.
    | Comment!
  • Dec. 20, 2011, 11:43 AM
    Oncothyreon (ONTY +2.1%) announces the filing of an Investigational New Drug application with the FDA for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1. Upon completion of the review, expects to initiate a Phase 1 trials.
    | Comment!
  • Nov. 16, 2011, 2:01 PM
    Oncothyreon (ONTY +10.3%) spikes higher after Wedbush lifts its PT to $31 from $15 (implies a 300%+ gain), and argues shares have a "highly asymmetric" risk-reward going into the expected Q1 2012 release of Phase III trial data for its Stimuvax cancer vaccine. (previously)
    | 3 Comments
  • Aug. 4, 2011, 9:05 AM
    Premarket gainers: GOLD +7%. KFT +6%. UN +5%. TDC +5%. SOLR +4%. SD +3%.
    Losers: DNDN -64%. ENTR -26%. GNOM -19%. VE -14%. ARO -14%. WLT -13%. LYG -10%. ONTY -9%. TS -8%. FRO -8%. BCS -8%. SPPI -7%. RIO -6%. LOGI -6%. ARMH -6%. KSS -5%. SDRL -5%. ASML -5%. MKTAY -5%. STM -5%. ALV -5%. MTG -5%. RIG -5%. ONNN -5%. BHP -4%. UBS -4%. ALU -4%. NWS -4%. CS -4%. STO -4%. ABB -4%. DB -4%. HMC -5%. ERIC -3%. WFR -3%. VALE -3%. GPS -3%. RDS.A -3%. FCX -3%. RCL -3%. ASX -3%. CCL -3%. PBR -3%. NOK -3%.
    | Comment!
  • Jul. 25, 2011, 12:20 PM
    Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung cancer drug Stimuvax. He asserts the drug is poorly designed, fails to improve lung cancer survival and is not likely to pass its phase III testing trials. 
    | 5 Comments
  • Jul. 20, 2011, 2:45 PM
    Oncothyreon (ONTY +16%) is higher today on a rumor that Phase III results of its cancer treatment drug Stimuvax are meeting endpoints. The stock has been heavily shorted recently - short interest now averages 2+ days to cover - adding to the stock's volatility.
    | Comment!
  • Apr. 29, 2011, 9:00 AM
    Premarket gainers: SPWRA  +40%. SPWRB +39%. SWKS +14%. GT +13%. CSTR +9%. SONC +8%. AXL +6%. JKS +6%. CIGX +5%. TSL +5%. LDK +4%. FSLR +5%. STP +4%. JASO +4%. JASO +4%. YGE +4%. SOL +3%. CAT +3%. LEG +3%. NBG +3%.
    Losers: KND -15%. RIMM -14%. ONTY -14%. IM -7%. RAS -6%. MTW -5%. VFC -4%. CMLP -4%.
    | Comment!
  • Jun. 17, 2010, 9:19 AM
    Premarket gainers: ONTY +19%. XOMA +9%. PIR +8%. CRIS +7%. CTIC +6%. NBIX +6%. FSLR +5%. KR +5%. CRUS +5%. AIB +4%. YRCW +4%. NVDA +4%. LYG +4%.
    Losers: FNM -15%. FRE -16%. DRE -6%.
    | 1 Comment
  • Dec. 10, 2009, 9:00 AM
    Premarket gainers: ONTY +10%. ING +4%. APC +4%. NLST +3%. FACT +3%. BCS +3%. IOC +3%. GFI +3%.
    Losers: SIGA -13%. IT -8%. CIEN -3%. LLY -3%.
    | Comment!
ONTY vs. ETF Alternatives
Company Description
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.
Sector: Healthcare
Industry: Biotechnology
Country: United States